• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Echo Therapeutics, Ferndale Pharma launch drug-device trial

April 27, 2010 By drugdelivery

ECTE logo

Echo Therapeutics Inc. (OTC:ECTE) and Ferndale Pharma Group Inc. enrolled the first patients in a clinical trial of Echo’s Prelude SkinPrep device and Ferndale’s 4 percent topical lidocaine, ahead of an application for 510(k) clearance for the drug-device combo from the Food & Drug Administration.

Franklin, Mass.-based Echo’s Prelude device is a needle-free, transdermal drug delivery system that ablates a thin layer of skin before a drug is applied.

In January the company said it was nearly ready to launch the clinical trial, having completed its development work on the product. The trial is designed to "evaluate the ability of the Prelude SkinPrep System to ablate the skin prior to application of OTC 4 percent lidocaine cream for local dermal anesthesia," according to a press release. Once it’s complete the companies plan to submit the 510(k) application to the FDA, likely later this year.

Echo said it licensed the rights to develop and commercialize the Prelude in the U.S. and the U.K. to Ferndale in May 2009, for an up-front payment of $750,000. Once the device wins FDA clearance another $750,000 milestone payment is due, plus $12.5 million "in milestone payments and guaranteed minimum royalty payments" and ongoing royalties on net sales, according to the release.

Echo chairman and president Dr. Patrick Mooney estimated in prepared remarks that the topical anesthetic market is worth more than $200 million a year and that the Prelude device "has the potential to grow it significantly."

Echo is also nearing readiness for a clinical trial of its Symphony tCGM transdermal glucose monitor, after a design breakthrough reduced the size of the device’s electrical component by a third.

Echo pulled in about $3.5 million in new investments late last year, $3 million from a private stock sale in November and another $562,000 from a group of backers in Philadelphia in December.

Filed Under: Business/Financial News, Drug-Device Combinations Tagged With: Echo Therapeutics Inc., Ferndale Pharma Group Inc.

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS